Quick Answer
MYRIAD GENETICS INC reported Operating Income Loss of -$387.20 million for the year ending 2025.
- MYRIAD GENETICS INC showed a decrease of -213.5% in Operating Income Loss from 2024 to 2025.
- This data is from MYRIAD GENETICS INC's annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2009 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2009 to 2025), MYRIAD GENETICS INC's Operating Income Loss has declined by 406.2%.
- Historical annual values: Fiscal year 2025: -$387.20 million | Fiscal year 2024: -$123.50 million | Fiscal year 2023: -$257.40 million | Fiscal year 2022: -$140.60 million | Fiscal year 2021: -$190.50 million | Fiscal year 2020: -$289.70 million | Fiscal year 2020: -$231.70 million | Fiscal year 2019: $7.60 million | Fiscal year 2018: $121.90 million | Fiscal year 2017: $44.00 million | Fiscal year 2016: $153.40 million | Fiscal year 2015: $133.60 million | Fiscal year 2014: $274.40 million | Fiscal year 2013: $228.00 million | Fiscal year 2012: $180.32 million | Fiscal year 2011: $157.78 million | Fiscal year 2010: $135.08 million | Fiscal year 2009: $126.46 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: